Association of Angiopoietin-Like Protein-8 Gene Variant (Rs2278426 (C/T)) in a Cohort of Egyptian Patients with Metabolic Syndrome: A Case-Control Study

Objective: This study was conducted to reveal the association of ANGPTL8 gene variant (Rs2278426 (C/T)) withmetabolic syndrome in a cohort of Egyptian patients. Materials and methods: This study is a case control study that included 150 patients with metabolic syndrome and 150 healthy control subjects. All subjects were submitted to history taking and thorough physical examination and laboratory analysis. Genomic DNA was extracted and ANGPTL8 gene SNP (rs2278426) was detected by 5’ nuclease assay. The tested genotypes included homozygous genotypes for C allele (CC), homozygous genotypes for T allele (TT) and heterozygous genotypes (CT). Results: A total of 300 subjects were included in the study; group 1 included 150 patients with metabolic syndrome. 21.3% were males and 78.7% were females, and group 2 had 150 healthy subjects. 17.3% were males, and 82.7% were females. In the current study, the metabolic syndrome group showed dysregulation of lipids and fasting plasma glucose (FPG) with a statistically significant increase in body anthropometric measures. There was no statistically significant difference in the distribution of the heterozygous genotype (C/T) relative to the wild-type genotype (C/C) in each of the two tested groups (p = 0.287 and 0.245 in the metabolic syndrome and control groups, respectively). Conclusions: There was no statistically significant difference in the genotype distribution of ANGPTL8 gene variant (Rs2278426) genotypes between the metabolic syndrome and control groups. The homozygous recessive genotype for T allele (TT) was not detected in both tested groups

MALAT1 and MEG3 genes expression in non-alcoholic fatty liver disease in type 2 diabetes mellitus patients: a case-control study

ABSTRACTAim of the study This study aims to investigate the nonalcoholic fatty liver disease (NAFLD) serum molecular profile among individuals diagnosed with type 2 diabetes (T2DM).Methods In this observational case-control investigation, 120 participants were included and subdivided forming 4 different groups as follows: group І: NAFLD non diabetic individuals, group ІІ: T2DM without NAFLD patients, group III: NAFLD diabetic patients and group IV: healthy control. MALAT1 and MEG3 expression in serum from all groups was measured.Results Expression of MALAT1 was upregulated in NAFLD and diabetic patients (p = 0.037 and 0.033 respectively). The cutoff value was determined for MALAT1 expression in NAFLD and diabetic by the ROC curve and was > 0.54 and > 0.67 respectively. By multivariate analysis, the only reliable indicator for MALAT1 expression in NAFLD and diabetics was determined to be ESR. Furthermore, we found that NAFLD patients showed greater MEG3 expression than those with T2DM (p = 0.033).Conclusion Expression of MALAT1 was upregulated in NAFLD and T2DM indicating that it might be an early diagnostic marker for both diseases and helps in the development of novel therapeutic agents. Moreover, MEG3 expression was higher among NAFLD patients than those NAFLD patients with T2DM, which suggests the feasibility of decreased MEG3 expression could be a viable predictive biomarker for early T2DM detection among NAFLD-diagnosed patients